FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013899237> ?p ?o ?g. }

• W2013899237 endingPage "797" @default.
• W2013899237 startingPage "789" @default.
• W2013899237 abstract "The efficacy and safety of recombinant human interferon gamma (rIFN-gamma) in the reduction of opportunistic disease in patients with advanced HIV-1 infection are assessed. A 12-month double-blind, placebo-controlled, multicenter, Phase III trial of rIFN-gamma in HIV-positive patients with CD4 < 100 x 10(9)/liter on stable antiretroviral therapy. Eighty-four patients were allocated treatment on a 1:1 basis to rIFN-gamma or placebo. Patients received rIFN-gamma 0.05 mg/m(2) or 0.9% saline subcutaneously three times weekly for 48 weeks (optional extension to 18 months). The primary end point was the incidence of opportunist infections (CDC categories B/C). Secondary end points included mortality, immunological, and virological parameters. Patients on placebo had a mean of 3.45 opportunist infections (OIs) in the first 48 weeks. Patients treated with rIFN-gamma had a mean of 1.71 OIs (p = 0.04). However, the model showed overdispersion and the inclusion of a dispersion factor raised the p value to 0.13. rIFN-gamma appeared to have a particular effect on the incidence of Candida, herpes simplex, and cytomegalovirus infections. Three-year survival in the rIFN-gamma arm was 28% compared to 18% in the placebo group (not significant). rIFN-gamma-associated side-effects of headache, fatigue, rigors, influenza-like symptoms, depression, myalgia, and granulocytopenia were reversible. There was no evidence for HIV activation. Although not significant, the trend towards decreased opportunistic infections and increased survival warrants consideration of further trials of rIFN-gamma. The study gives additional information on the safety profile of this cytokine." @default.
• W2013899237 created "2016-06-24" @default.
• W2013899237 creator A5012451434 @default.
• W2013899237 creator A5021283744 @default.
• W2013899237 creator A5023803089 @default.
• W2013899237 creator A5026550623 @default.
• W2013899237 creator A5030467691 @default.
• W2013899237 creator A5031161184 @default.
• W2013899237 creator A5060708175 @default.
• W2013899237 creator A5078054016 @default.
• W2013899237 creator A5083752740 @default.
• W2013899237 creator A5084224194 @default.
• W2013899237 creator A5089963460 @default.
• W2013899237 date "2001-06-10" @default.
• W2013899237 modified "2023-09-27" @default.
• W2013899237 title "A Phase III Study of Recombinant Human Interferon Gamma to Prevent Opportunistic Infections in Advanced HIV Disease" @default.
• W2013899237 cites W1970356423 @default.
• W2013899237 cites W1971604280 @default.
• W2013899237 cites W1976694550 @default.
• W2013899237 cites W1979129905 @default.
• W2013899237 cites W1991337645 @default.
• W2013899237 cites W1995225418 @default.
• W2013899237 cites W2005150291 @default.
• W2013899237 cites W2018541015 @default.
• W2013899237 cites W2020223264 @default.
• W2013899237 cites W2024791349 @default.
• W2013899237 cites W2027548834 @default.
• W2013899237 cites W2037723969 @default.
• W2013899237 cites W2038256546 @default.
• W2013899237 cites W2040476677 @default.
• W2013899237 cites W2055397536 @default.
• W2013899237 cites W2063140237 @default.
• W2013899237 cites W2065158430 @default.
• W2013899237 cites W2068871282 @default.
• W2013899237 cites W2077911026 @default.
• W2013899237 cites W2085089692 @default.
• W2013899237 cites W2089262366 @default.
• W2013899237 cites W2106774411 @default.
• W2013899237 cites W2111023076 @default.
• W2013899237 cites W2141896182 @default.
• W2013899237 cites W2157376708 @default.
• W2013899237 cites W2326805633 @default.
• W2013899237 cites W2333546620 @default.
• W2013899237 cites W2334923455 @default.
• W2013899237 cites W2520163263 @default.
• W2013899237 cites W299799878 @default.
• W2013899237 cites W4238237268 @default.
• W2013899237 cites W4242377575 @default.
• W2013899237 cites W4313305965 @default.
• W2013899237 cites W4313347866 @default.
• W2013899237 doi "https://doi.org/10.1089/088922201750251981" @default.
• W2013899237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11429120" @default.
• W2013899237 hasPublicationYear "2001" @default.
• W2013899237 type Work @default.
• W2013899237 sameAs 2013899237 @default.
• W2013899237 citedByCount "45" @default.
• W2013899237 countsByYear W20138992372012 @default.
• W2013899237 countsByYear W20138992372013 @default.
• W2013899237 countsByYear W20138992372014 @default.
• W2013899237 countsByYear W20138992372015 @default.
• W2013899237 countsByYear W20138992372016 @default.
• W2013899237 countsByYear W20138992372017 @default.
• W2013899237 countsByYear W20138992372018 @default.
• W2013899237 countsByYear W20138992372019 @default.
• W2013899237 countsByYear W20138992372020 @default.
• W2013899237 countsByYear W20138992372021 @default.
• W2013899237 countsByYear W20138992372022 @default.
• W2013899237 countsByYear W20138992372023 @default.
• W2013899237 crossrefType "journal-article" @default.
• W2013899237 hasAuthorship W2013899237A5012451434 @default.
• W2013899237 hasAuthorship W2013899237A5021283744 @default.
• W2013899237 hasAuthorship W2013899237A5023803089 @default.
• W2013899237 hasAuthorship W2013899237A5026550623 @default.
• W2013899237 hasAuthorship W2013899237A5030467691 @default.
• W2013899237 hasAuthorship W2013899237A5031161184 @default.
• W2013899237 hasAuthorship W2013899237A5060708175 @default.
• W2013899237 hasAuthorship W2013899237A5078054016 @default.
• W2013899237 hasAuthorship W2013899237A5083752740 @default.
• W2013899237 hasAuthorship W2013899237A5084224194 @default.
• W2013899237 hasAuthorship W2013899237A5089963460 @default.
• W2013899237 hasConcept C120665830 @default.
• W2013899237 hasConcept C121332964 @default.
• W2013899237 hasConcept C126322002 @default.
• W2013899237 hasConcept C141071460 @default.
• W2013899237 hasConcept C142724271 @default.
• W2013899237 hasConcept C203014093 @default.
• W2013899237 hasConcept C203092338 @default.
• W2013899237 hasConcept C204787440 @default.
• W2013899237 hasConcept C27081682 @default.
• W2013899237 hasConcept C2778616394 @default.
• W2013899237 hasConcept C535046627 @default.
• W2013899237 hasConcept C61511704 @default.
• W2013899237 hasConcept C71924100 @default.
• W2013899237 hasConcept C90924648 @default.
• W2013899237 hasConceptScore W2013899237C120665830 @default.
• W2013899237 hasConceptScore W2013899237C121332964 @default.
• W2013899237 hasConceptScore W2013899237C126322002 @default.
• W2013899237 hasConceptScore W2013899237C141071460 @default.

• next